Brief: Enlivex Announces The Enrollment And Dosing Of The First 10 Patient In The Randomized Phase II Stage Of Its Allocetra Trial In Patients With Moderate To Severe Knee Osteoarthritis
12/11/2024 13:14
Nov 12 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX ANNOUNCES THE ENROLLMENT AND DOSING OF THE FIRST
10
PATIENT IN THE RANDOMIZED PHASE II STAGE OF ITS ALLOCETRA TRIAL
IN PATIENTS WITH MODERATE TO SEVERE KNEE OSTEOARTHRITIS
Source text: ID:nGNXbY9gM6
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment